Genomic and Evolutionary Characterization of Concurrent Intraductal Carcinoma and Adenocarcinoma of the Prostate.


Journal

Cancer research
ISSN: 1538-7445
Titre abrégé: Cancer Res
Pays: United States
ID NLM: 2984705R

Informations de publication

Date de publication:
17 Oct 2023
Historique:
accepted: 13 10 2023
received: 18 04 2023
revised: 31 07 2023
medline: 17 10 2023
pubmed: 17 10 2023
entrez: 17 10 2023
Statut: aheadofprint

Résumé

Intraductal carcinoma of the prostate (IDC-P) is a lethal prostate cancer subtype that generally co-exists with invasive high-grade prostate acinar adenocarcinoma (PAC) but exhibits distinct biological features compared to concomitant adenocarcinoma. In this study, we performed whole-exome, RNA, and DNA-methylation sequencing of IDC-P, concurrent invasive high-grade PAC lesions, and adjacent normal prostate tissues isolated from 22 radical prostatectomy specimens. Three evolutionary patterns of concurrent IDC-P and PAC were identified: early divergent, late divergent, and clonally distant. In contrast to those with a late divergent evolutionary pattern, tumors with clonally distant and early divergent evolutionary patterns showed higher genomic, epigenomic, transcriptional, and pathological heterogeneity between IDC-P and PAC. Compared to co-existing PAC, IDC-P displayed increased expression of adverse prognosis-associated genes. Survival analysis based on an independent cohort of 505 metastatic prostate cancer patients revealed that IDC-P carriers with lower risk ISUP grade 1-4 adenocarcinoma displayed a castration-resistant free survival as poor as those with the highest risk ISUP grade 5 tumors that lacked concurrent IDC-P. Furthermore, IDC-P exhibited robust cell-cycle progression and androgen receptor activities, characterized by an enrichment of cellular proliferation-associated master regulators and genes involved in intratumoral androgen biosynthesis. Overall, this study provides a molecular groundwork for the aggressive behavior of IDC-P and could help identify potential strategies to improve treatment of IDC-P.

Identifiants

pubmed: 37847513
pii: 729613
doi: 10.1158/0008-5472.CAN-23-1176
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Jinge Zhao (J)

West China Hospital, Chengdu, China.

Sha Zhu (S)

West China Hospital, Chengdu, China.

Ling Nie (L)

Department of Pathology and Laboratory of Pathology, State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, China.

Mengni Zhang (M)

Pathology Department, West China Hospital, West China Medical School,Sichuan University, Chengdu, China.

Linmao Zheng (L)

Department of Pathology, West China Hospital, Sichuan University, China.

Nanwei Xu (N)

West China Hospital, Chengdu, China.

Diming Cai (D)

West China Hospital, Chengdu, China.

Xiaomeng Sun (X)

GloriousMed Clinical Laboratory Co., Ltd., Shanghai, Shanghai, China.

Junru Chen (J)

West China Hospital, Chengdu, China.

Jindong Dai (J)

West China Hospital, Chengdu, China.

Yuchao Ni (Y)

West China Hospital, Chengdu, China.

Zhipeng Wang (Z)

West China Hospital, Chengdu, China.

Xingming Zhang (X)

West China Hospital, Chengdu, China.

Jiayu Liang (J)

institute of urology, chengdu, China.

Yuntian Chen (Y)

West China Hospital of Sichuan University, Chengdu, Sichuan, China.

Xu Hu (X)

Sichuan University West China Hospital, Chengdu, China.

Xiuyi Pan (X)

West China Hospital, West China Medical School, Chengdu, China.

Xiaoxue Yin (X)

West China Hospital, West China Medical School, Chengdu, China.

Haoyang Liu (H)

West China Hospital, Chengdu, China.

Fengnian Zhao (F)

West China Hospital, Chengdu, China.

Bei Zhang (B)

3D Medicines Inc., shanghai, China.

Hao Chen (H)

3D Medicines Inc., Shanghai, China.

Jiashun Miao (J)

3D Medicines Inc., Shanghai, China.

Cong Qin (C)

3D Medicines Inc., Shanghai, China.

Xiaochen Zhao (X)

The Medical Department, 3D Medicines Inc. Shanghai, P.R. China, Shanghai, China.

Jin Yao (J)

West China Hospital of Sichuan University, Chengdu, Sichuan, China.

Zhenhua Liu (Z)

West China Hospital, Chengdu, China.

Banghua Liao (B)

West China Hospital of Sichuan University, chengdu, China.

Qiang Wei (Q)

West China Hospital of Sichuan University, Chengdu, China.

Xiang Li (X)

West China Hospital, West China Medical School, Sichuan University, Chengdu, China.

Jiyan Liu (J)

West China Hospital of Sichuan University, Chengdu, Sichuan, China.

Allen C Gao (AC)

University of California, Davis, Sacramento, CA, United States.

Haojie Huang (H)

Mayo Clinic, Rochester, MN, United States.

Peng-Fei Shen (PF)

West China Hospital of Sichuan University, Chengdu, Sichuan, China.

Ni Chen (N)

West China Hospital, West China Medical School, Chengdu, China.

Hao Zeng (H)

West China Hospital of Sichuan University, Chengdu, Sichuan, China.

Guangxi Sun (G)

West China Hospital, Chengdu, China.

Classifications MeSH